SK2694A3 - Pharmaceutical agent for treatment of motor neuron diseases - Google Patents
Pharmaceutical agent for treatment of motor neuron diseases Download PDFInfo
- Publication number
- SK2694A3 SK2694A3 SK26-94A SK2694A SK2694A3 SK 2694 A3 SK2694 A3 SK 2694A3 SK 2694 A SK2694 A SK 2694A SK 2694 A3 SK2694 A3 SK 2694A3
- Authority
- SK
- Slovakia
- Prior art keywords
- bdnf
- motor neurons
- motor
- ngf
- compound
- Prior art date
Links
- 208000005264 motor neuron disease Diseases 0.000 title claims abstract description 31
- 238000011282 treatment Methods 0.000 title claims abstract description 27
- 239000008177 pharmaceutical agent Substances 0.000 title 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims abstract description 140
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims abstract description 140
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims abstract description 30
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims abstract description 30
- 210000002161 motor neuron Anatomy 0.000 claims description 122
- 108090000742 Neurotrophin 3 Proteins 0.000 claims description 97
- 102100029268 Neurotrophin-3 Human genes 0.000 claims description 97
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 86
- 238000000034 method Methods 0.000 claims description 77
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 38
- 239000003900 neurotrophic factor Substances 0.000 claims description 36
- 230000004083 survival effect Effects 0.000 claims description 36
- 239000000126 substance Substances 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 33
- 230000004069 differentiation Effects 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 230000012010 growth Effects 0.000 claims description 20
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 19
- 238000012360 testing method Methods 0.000 claims description 16
- 210000005036 nerve Anatomy 0.000 claims description 14
- 208000000474 Poliomyelitis Diseases 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 11
- 239000002609 medium Substances 0.000 claims description 11
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 208000014674 injury Diseases 0.000 claims description 9
- 206010003694 Atrophy Diseases 0.000 claims description 8
- 230000037444 atrophy Effects 0.000 claims description 8
- 230000006378 damage Effects 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 7
- -1 NGF compound Chemical class 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 230000007441 retrograde transport Effects 0.000 claims description 6
- 230000032258 transport Effects 0.000 claims description 6
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 4
- 229920002684 Sepharose Polymers 0.000 claims description 4
- 230000002596 correlated effect Effects 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 230000006764 neuronal dysfunction Effects 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 208000028389 Nerve injury Diseases 0.000 claims description 3
- 239000012506 Sephacryl® Substances 0.000 claims description 3
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims description 3
- 208000026481 Werdnig-Hoffmann disease Diseases 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- 230000008764 nerve damage Effects 0.000 claims description 3
- 201000008752 progressive muscular atrophy Diseases 0.000 claims description 3
- 210000001032 spinal nerve Anatomy 0.000 claims description 3
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 230000000366 juvenile effect Effects 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 239000001963 growth medium Substances 0.000 claims 4
- 238000007865 diluting Methods 0.000 claims 2
- 238000003306 harvesting Methods 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 35
- 210000000278 spinal cord Anatomy 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 31
- 241000700159 Rattus Species 0.000 description 20
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 18
- 230000001965 increasing effect Effects 0.000 description 18
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 17
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
- 239000000463 material Substances 0.000 description 15
- 239000002953 phosphate buffered saline Substances 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 10
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 description 9
- 238000004166 bioassay Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 229960000554 metrizamide Drugs 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 210000003594 spinal ganglia Anatomy 0.000 description 8
- 210000000256 facial nerve Anatomy 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 208000026072 Motor neurone disease Diseases 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 210000005013 brain tissue Anatomy 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 239000007943 implant Substances 0.000 description 6
- 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 230000001537 neural effect Effects 0.000 description 5
- 239000007987 MES buffer Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010028347 Muscle twitching Diseases 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 4
- 108090000631 Trypsin Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000012588 trypsin Substances 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- 238000007747 plating Methods 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000004445 quantitative analysis Methods 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- JJCWKVUUIFLXNZ-UHFFFAOYSA-M 2-hydroxyethyl(trimethyl)azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCO JJCWKVUUIFLXNZ-UHFFFAOYSA-M 0.000 description 2
- 108090000668 Annexin A2 Proteins 0.000 description 2
- 102100034613 Annexin A2 Human genes 0.000 description 2
- 108090000669 Annexin A4 Proteins 0.000 description 2
- 102100034612 Annexin A4 Human genes 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000021401 Facial Nerve injury Diseases 0.000 description 2
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010049816 Muscle tightness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 239000005700 Putrescine Substances 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000007998 bicine buffer Substances 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 239000012468 concentrated sample Substances 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 2
- 201000010901 lateral sclerosis Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 2
- 229960002362 neostigmine Drugs 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 229940032018 neurotrophin 3 Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000035778 pathophysiological process Effects 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229960001471 sodium selenite Drugs 0.000 description 2
- 239000011781 sodium selenite Substances 0.000 description 2
- 235000015921 sodium selenite Nutrition 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 210000000273 spinal nerve root Anatomy 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- MXNRLFUSFKVQSK-UHFFFAOYSA-N 2-Amino-6-(trimethylazaniumyl)hexanoate Chemical compound C[N+](C)(C)CCCCC(N)C([O-])=O MXNRLFUSFKVQSK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 101100335897 Caenorhabditis elegans gly-9 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010058936 Cohn fraction V Proteins 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000001308 Fasciculation Diseases 0.000 description 1
- 108010019393 Fibrin Foam Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000581940 Homo sapiens Napsin-A Proteins 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108010023244 Lactoperoxidase Proteins 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OKIBNKKYNPBDRS-UHFFFAOYSA-N Mefluidide Chemical compound CC(=O)NC1=CC(NS(=O)(=O)C(F)(F)F)=C(C)C=C1C OKIBNKKYNPBDRS-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102100027343 Napsin-A Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100109397 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-8 gene Proteins 0.000 description 1
- 101100386050 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cys-14 gene Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- QPFYXYFORQJZEC-FOCLMDBBSA-N Phenazopyridine Chemical compound NC1=NC(N)=CC=C1\N=N\C1=CC=CC=C1 QPFYXYFORQJZEC-FOCLMDBBSA-N 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039670 Sciatic nerve injury Diseases 0.000 description 1
- 206010041415 Spastic paralysis Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 206010062910 Vascular infections Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004960 anterior grey column Anatomy 0.000 description 1
- 210000002226 anterior horn cell Anatomy 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007863 gel particle Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000012296 in situ hybridization assay Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 230000001095 motoneuron effect Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229940099459 n-acetylmethionine Drugs 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 201000002241 progressive bulbar palsy Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940070891 pyridium Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- ZSLZBFCDCINBPY-YHBLMJDYSA-N s-[2-[3-[[(2r)-4-[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] ethanethioate Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS[14C](=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-YHBLMJDYSA-N 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 210000000413 sensory ganglia Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001646 thyrotropic effect Effects 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 102000015534 trkB Receptor Human genes 0.000 description 1
- 108010064880 trkB Receptor Proteins 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 206010055031 vascular neoplasm Diseases 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Physical Water Treatments (AREA)
- Water Treatment By Electricity Or Magnetism (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Water Treatment By Sorption (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72770491A | 1991-07-10 | 1991-07-10 | |
| PCT/US1992/004228 WO1993001300A1 (en) | 1991-07-10 | 1992-05-19 | Methods of treatment of motor neuron diseases using members of the bdnf/nt-3/ngf family of molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK2694A3 true SK2694A3 (en) | 1995-02-08 |
Family
ID=24923677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK26-94A SK2694A3 (en) | 1991-07-10 | 1992-05-19 | Pharmaceutical agent for treatment of motor neuron diseases |
Country Status (20)
| Country | Link |
|---|---|
| EP (2) | EP0593516B1 (da) |
| JP (1) | JPH06509094A (da) |
| CN (1) | CN1065768C (da) |
| AT (1) | ATE202939T1 (da) |
| AU (2) | AU675409B2 (da) |
| CA (1) | CA2113083A1 (da) |
| DE (1) | DE69231930T2 (da) |
| DK (1) | DK0593516T3 (da) |
| ES (1) | ES2157903T3 (da) |
| FI (1) | FI940098A7 (da) |
| GR (1) | GR3036776T3 (da) |
| HU (1) | HUT70275A (da) |
| IE (1) | IE921602A1 (da) |
| IL (1) | IL101928A0 (da) |
| NO (1) | NO940084L (da) |
| PT (1) | PT100501A (da) |
| RU (1) | RU94016525A (da) |
| SK (1) | SK2694A3 (da) |
| WO (1) | WO1993001300A1 (da) |
| ZA (1) | ZA923639B (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993025684A1 (en) * | 1992-06-12 | 1993-12-23 | Regeneron Pharmaceuticals, Inc. | Therapeutic and diagnostic methods based on neurotrophin-4 expression |
| FR2717496B1 (fr) * | 1994-03-18 | 1996-04-12 | Rhone Poulenc Rorer Sa | Virus recombinants, préparation et utilisation en thérapie génique. |
| CN1112215C (zh) * | 1999-12-28 | 2003-06-25 | 潘晓东 | 神经生长因子在治疗有机溶剂中毒性周围神经病中的用途 |
| AU2001259453B2 (en) | 2000-05-05 | 2006-08-31 | Beth Israel Deaconess Medical Center | Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis |
| WO2008156418A1 (en) * | 2007-06-19 | 2008-12-24 | Astrazeneca Ab | A method for screening or diagnosis of postpolio syndrome and fibromyalgia |
| MX2010001395A (es) * | 2007-08-10 | 2010-03-10 | Regeneron Pharma | Anticuerpos humanos de alta afinidad de factor de crecimiento de nervio humano. |
| WO2014111525A2 (en) | 2013-01-18 | 2014-07-24 | Anaxomics Biotech, Sl | New combination therapies for treating nervous system diseases |
| WO2016210325A1 (en) | 2015-06-26 | 2016-12-29 | C.R. Bard, Inc. | Connector interface for ecg-based catheter positioning system |
| WO2023164311A2 (en) * | 2022-02-28 | 2023-08-31 | Bioincept, Llc | Compositions and methods of treating amyotrophic lateral sclerosis (als) and related disorders |
| GB202303495D0 (en) * | 2023-03-09 | 2023-04-26 | Ucl Business Ltd | Therapy for charcot-marie-tooth disease |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4923696A (en) * | 1987-05-04 | 1990-05-08 | Baylor College Of Medicine | Method to prepare a neurotrophic composition |
| GR1000980B (el) * | 1989-08-30 | 1993-03-31 | Max Planck Gesellschaft | Νευροτροφινη-3,ενας νεος neυροτροφικος παραγοντας που σχετιζεται με τον παραγοντα αναπτυξης νευρων και τον νευροτροφικο παραγοντα που προερχεται απο τον εγκεφαλο. |
| US5229500A (en) * | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
| IE903130A1 (en) * | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
-
1992
- 1992-05-19 RU RU94016525/14A patent/RU94016525A/ru unknown
- 1992-05-19 EP EP92912453A patent/EP0593516B1/en not_active Expired - Lifetime
- 1992-05-19 SK SK26-94A patent/SK2694A3/sk unknown
- 1992-05-19 PT PT100501A patent/PT100501A/pt not_active Application Discontinuation
- 1992-05-19 ZA ZA923639A patent/ZA923639B/xx unknown
- 1992-05-19 DE DE69231930T patent/DE69231930T2/de not_active Expired - Lifetime
- 1992-05-19 WO PCT/US1992/004228 patent/WO1993001300A1/en not_active Ceased
- 1992-05-19 CA CA2113083A patent/CA2113083A1/en not_active Abandoned
- 1992-05-19 AU AU20095/92A patent/AU675409B2/en not_active Ceased
- 1992-05-19 JP JP5502202A patent/JPH06509094A/ja active Pending
- 1992-05-19 EP EP96111711A patent/EP0755682A1/en not_active Withdrawn
- 1992-05-19 ES ES92912453T patent/ES2157903T3/es not_active Expired - Lifetime
- 1992-05-19 HU HU9400063A patent/HUT70275A/hu unknown
- 1992-05-19 CN CN92105070A patent/CN1065768C/zh not_active Expired - Fee Related
- 1992-05-19 AT AT92912453T patent/ATE202939T1/de not_active IP Right Cessation
- 1992-05-19 DK DK92912453T patent/DK0593516T3/da active
- 1992-05-19 IL IL101928A patent/IL101928A0/xx unknown
- 1992-07-01 IE IE160292A patent/IE921602A1/en not_active Application Discontinuation
-
1994
- 1994-01-10 FI FI940098A patent/FI940098A7/fi not_active Application Discontinuation
- 1994-01-10 NO NO940084A patent/NO940084L/no unknown
-
1996
- 1996-11-08 AU AU70676/96A patent/AU7067696A/en not_active Abandoned
-
2001
- 2001-10-03 GR GR20010401637T patent/GR3036776T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HU9400063D0 (en) | 1994-06-28 |
| IE921602A1 (en) | 1993-01-13 |
| PT100501A (pt) | 1993-09-30 |
| AU2009592A (en) | 1993-02-11 |
| ATE202939T1 (de) | 2001-07-15 |
| GR3036776T3 (en) | 2002-01-31 |
| RU94016525A (ru) | 1996-06-10 |
| EP0593516A4 (en) | 1995-01-18 |
| NO940084D0 (no) | 1994-01-10 |
| JPH06509094A (ja) | 1994-10-13 |
| AU7067696A (en) | 1997-01-16 |
| DE69231930T2 (de) | 2002-04-11 |
| AU675409B2 (en) | 1997-02-06 |
| ZA923639B (en) | 1993-02-24 |
| FI940098A7 (fi) | 1994-03-10 |
| CA2113083A1 (en) | 1993-01-21 |
| WO1993001300A1 (en) | 1993-01-21 |
| EP0755682A1 (en) | 1997-01-29 |
| EP0593516A1 (en) | 1994-04-27 |
| NO940084L (no) | 1994-03-08 |
| HUT70275A (en) | 1995-09-28 |
| IL101928A0 (en) | 1992-12-30 |
| EP0593516B1 (en) | 2001-07-11 |
| DE69231930D1 (de) | 2001-08-16 |
| DK0593516T3 (da) | 2001-09-17 |
| CN1065768C (zh) | 2001-05-16 |
| CN1071585A (zh) | 1993-05-05 |
| ES2157903T3 (es) | 2001-09-01 |
| FI940098A0 (fi) | 1994-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hagg et al. | Ciliary neurotrophic factor prevents neuronal degeneration and promotes low affinity NGF receptor expression in the adult rat CNS | |
| Mantyh et al. | Beta 2-adrenergic receptors are expressed by glia in vivo in the normal and injured central nervous system in the rat, rabbit, and human | |
| Sjöberg et al. | Insulin-like growth factor (IGF-1) as a stimulator of regeneration in the freeze-injured rat sciatic nerve | |
| EP0890105B1 (en) | Methods related to Alzheimer's disease for diagnosis, manufacture of medicaments and screening of substances and beta-amyloid related peptides | |
| CA2040404A1 (en) | Ciliary neurotrophic factor | |
| Herrero et al. | GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys | |
| Brecknell et al. | Functional and anatomical reconstruction of the 6-hydroxydopamine lesioned nigrostriatal system of the adult rat | |
| Kaechi et al. | 4-Methylcatechol, an inducer of nerve growth factor synthesis, enhances peripheral nerve regeneration across nerve gaps. | |
| Wen et al. | Protective effect of basic fibroblast growth factor-heparin and neurotoxic effect of platelet factor 4 on ischemic neuronal loss and learning disability in gerbils | |
| SK2694A3 (en) | Pharmaceutical agent for treatment of motor neuron diseases | |
| Knusel et al. | Intraparenchymal NGF injections in adult and aged rats induce long-lasting Trk tyrosine phosphorylation | |
| Blum et al. | Chronic continuous infusion of (−) nicotine reduces basic fibroblast growth factor messenger RNA levels in the ventral midbrain of the intact but not of the 6-hydroxydopamine-lesioned rat | |
| Gu et al. | Responses in the aged rat brain after total immunolesion | |
| Bäckman et al. | Effects of transferrin receptor antibody-NGF conjugate on young and aged septal transplants in oculo | |
| Kishino et al. | Enhancement of BDNF and activated-ERK immunoreactivity in spinal motor neurons after peripheral administration of BDNF | |
| Joosten et al. | Alpha-melanocyte stimulating hormone promotes regrowth of injured axons in the adult rat spinal cord | |
| WO1992010200A1 (en) | Functional interactions between glial s-100b and central nervous system serotonergic neurons | |
| WO1994020125A1 (en) | Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5) | |
| AU9368498A (en) | Neuronal rescue agent | |
| Ferguson et al. | Chicken NGF and non‐NGF trophic factor synthesis and release by sciatic nerves in vitro | |
| Williams et al. | Altered NGF response but not release in the aged septo-hippocampal cholinergic system | |
| Wagey et al. | Phosphatidylinositol 3-kinase activity in murine motoneuron disease: the progressive motor neuropathy mouse | |
| WO1993009798A1 (en) | Therapeutic and diagnostic methods based on tissue specific nt-3 expression and receptor binding | |
| AU9676598A (en) | Apolipoprotein e/growth factor complexes and methods of use | |
| EP2026831A2 (en) | Methods and compositions for treating and preventing peripheral nerve damage |